INFLAMMATORY BOWEL DISEASE

This study tests whether a fecal transplant (FMT) can safely and effectively treat recurrent C. difficile infections in children, including those with inflammatory bowel disease (IBD). Researchers will give FMT to 250 children aged 3-21 and track whether the infection comes back.…

This study tests an automated tool that uses patient risk levels to remind people with inflammatory bowel disease (IBD) when they need follow-up appointments. Researchers will compare how often patients are overdue for visits and whether this leads to fewer emergency room trips o…

This study looks at whether continuous heart rate variability (HRV) monitoring can predict how well patients with inflammatory bowel disease (IBD) respond to biologic therapies like infliximab or vedolizumab. Researchers will track HRV in 100 patients starting treatment and compa…

This long-running study at Johns Hopkins aims to identify the genetic and environmental factors that cause inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Researchers are enrolling 2,500 participants — including patients, their family members, …

This study aims to better understand inflammatory bowel disease (IBD) by collecting tissue samples from 1,100 people undergoing endoscopy or bowel surgery. Researchers will analyze gene activity, proteins, and gut microbes to learn what causes the disease. The study includes both…

This study aims to find genes that cause inflammatory bowel disease (IBD) specifically in African Americans. Researchers will collect health information and blood samples from 2,400 African Americans, both with and without IBD. No treatment is given—the goal is to better understa…

This study observes 562 adults with inflammatory bowel disease (Crohn's disease or ulcerative colitis) who are starting or switching to Hyrimoz®, a biosimilar of adalimumab. Researchers will track how many patients continue the treatment after 6 months and why some stop, such as …

This study looks at whether the shingles vaccine (HZ/su) is safe for pregnant women aged 18-49 with weakened immune systems. Researchers will track about 2,800 women to see if the vaccine raises the risk of birth defects or other problems in their babies. The goal is to provide r…